SFTPD

Across TCGA pan-cancer cohorts, SFTPD mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SFTPD data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SFTPD mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SFTPD expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, UCEC, and LSCC are the cancer types where SFTPD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.338	0.993	.006	3	view →
UCEC	DFS	Median	All	0.554	1.000	.040	2	view →
LSCC	DFS	Quartile	All	0.815	0.294	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SFTPD–LUAD (DFS)

Open the LUAD breakdown →